SCHEDULE 13D/A: Armata Extends Key Debt, Warrants, and Voting Agreements

Sentiment:

Schedule 13D Amendment 26 January 2026 9:05 PM

Armata Pharmaceuticals, Inc. and Innoviva, Inc. have extended maturity dates for several credit agreements and expiration dates for warrants and a voting agreement, solidifying their financial relationship.

Delay expectedThe maturity dates for four secured convertible credit and security agreements were extended from their previous terms to June 1, 2027.The expiration dates for four warrant certificates were extended to January 26, 2031.The expiration date of the Second Amended and Restated Voting Agreement was extended to January 26, 2031 (or earlier upon FDA approval).

Capital raiseThe filing details a convertible loan held by Innoviva, which can be converted into 19,736,843 shares of Common Stock, representing a past capital raise that could lead to future equity.Innoviva also holds warrants exercisable for 10,653,847 shares of Common Stock, representing another form of past capital raise with potential future equity conversion.

Summary

Innoviva, Inc. and its subsidiary, Innoviva Strategic Opportunities LLC (collectively, 'Reporting Persons'), filed Amendment No. 14 to their Schedule 13D regarding their beneficial ownership in Armata Pharmaceuticals, Inc.
The amendment details the extension of maturity dates for four secured convertible credit and security agreements (Convertible Credit Agreement, July 2023 Credit Agreement, March 2024 Credit Agreement, and March 2025 Credit Agreement) to June 1, 2027.
Expiration dates for four warrant certificates (January 2021, March 2021, February 2022, and March 2022 Warrants) were extended to January 26, 2031.
The expiration date of the Second Amended and Restated Voting Agreement was also extended to the earlier of January 26, 2031, or approval by the U.S. Food and Drug Administration (FDA) of any of Armata's product candidates for marketing and commercial distribution.
As of the filing date, the Reporting Persons collectively beneficially own 55,467,459 shares of Common Stock, representing approximately 83.1% of Armata's outstanding shares.
This beneficial ownership includes 25,076,769 currently owned shares, 10,653,847 shares issuable upon warrant exercise, and 19,736,843 shares issuable upon conversion of a convertible loan (excluding accrued interest).

Sentiment

Score: 7

Explanation: The extensions provide stability and continued financial support from a major shareholder, which is positive for Armata's operational runway. However, it also highlights ongoing dependence and potential future dilution, leading to a moderately positive sentiment.

Positives

The extensions of credit agreement maturity dates provide Armata with continued financial runway and stability, deferring repayment obligations.
Innoviva's ongoing commitment, evidenced by these extensions, signals continued support for Armata's strategic objectives and product development.
Extended warrant expiration dates allow Innoviva more time to potentially realize value from their investment, aligning their long-term interests with Armata's success.
The voting agreement extension, tied to FDA approval, indicates a shared long-term vision focused on achieving regulatory milestones.

Negatives

Armata's continued high reliance on Innoviva for financing and strategic support indicates a lack of diversified funding sources.
The significant beneficial ownership (83.1%) by Innoviva suggests limited liquidity and control for other shareholders.
Potential future dilution from the conversion of the convertible loan (19,736,843 shares) and exercise of warrants (10,653,847 shares) could impact existing shareholders.

Risks

High concentration of ownership and control by Innoviva, Inc. and its subsidiary, which could influence corporate decisions in ways not always aligned with minority shareholders.
Dependence on Innoviva for ongoing financing, which could pose a risk if Innoviva's strategic priorities or financial capacity change.
Potential for significant future dilution if the convertible loan is converted and warrants are exercised, impacting the per-share value for existing shareholders.
The success of Armata's product candidates and subsequent FDA approval is critical for the long-term viability and value creation, as indicated by the voting agreement's expiration clause.

Future Outlook

The extensions of credit agreements, warrants, and the voting agreement suggest a continued long-term commitment from Innoviva to Armata. The explicit link of the voting agreement's expiration to FDA approval of Armata's product candidates indicates a strategic focus on achieving regulatory milestones and commercialization, implying an expectation of continued development and potential market entry.

Industry Context

In the biotechnology and pharmaceutical sectors, companies often rely on significant investments from strategic partners or venture capital for research, development, and clinical trials. Extensions of financing agreements and warrants, particularly from a major shareholder, are common mechanisms to provide necessary capital and runway for drug development, which is a lengthy and capital-intensive process. This filing reflects a typical scenario where a key investor continues to support a development-stage company through critical phases, aiming for future commercial success.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Voting Agreement Amendment	The Second Amended and Restated Voting Agreement's 'Expiration Date' definition was amended to be the earlier of January 26, 2031, or FDA approval of any of the Issuer's product candidates.	2026-01-23	This amendment extends the period during which Innoviva's voting rights and influence are governed by this agreement, potentially maintaining their significant control over corporate governance for a longer duration, or until a key commercialization milestone is achieved.

Related Party Transactions

Innoviva, Inc. and Innoviva Strategic Opportunities LLC are the Reporting Persons and are engaged in multiple financial agreements (credit agreements, warrants, voting agreement) with Armata Pharmaceuticals, Inc., indicating significant related-party dealings.

Stakeholder Impact

Shareholders: Potential for long-term stability due to continued financing, but also risk of significant future dilution from convertible instruments and continued high concentration of ownership by Innoviva.
Creditors (Innoviva Sub): Extended maturity dates for credit agreements defer repayment, but also extend the period of their investment and potential returns.
Employees: Continued operations and development supported by extended financing provide job security and a clear path forward for product development.

Next Steps

Continued development of Armata's product candidates towards U.S. Food and Drug Administration (FDA) approval for marketing and commercial distribution.
Potential conversion of the convertible loan and exercise of warrants by Innoviva, Inc. at future dates.

Key Dates

Date	Description
2020-02-14	Initial Statement of Beneficial Ownership on Schedule 13D filed by Innoviva, Inc.
2021-01-26	Original issue date of the January 2021 Warrant.
2021-03-17	Original issue date of the March 2021 Warrant.
2022-02-09	Original issue date of the February 2022 Warrant and the Second Amended and Restated Voting Agreement.
2022-03-31	Original issue date of the March 2022 Warrant.
2023-01-10	Date of the secured convertible credit and security agreement (Convertible Credit Agreement).
2023-07-10	Date of the credit and security agreement (July 2023 Credit Agreement).
2024-03-04	Date of the credit and security agreement (March 2024 Credit Agreement).
2025-03-12	Date of the credit and security agreement (March 2025 Credit Agreement).
2025-11-04	Date as of which 36,329,842 shares of Common Stock were outstanding, as per Issuer's Form 10-Q.
2025-11-12	Date of Issuer's Quarterly Report on Form 10-Q filed with the SEC.
2026-01-23	Date of event requiring this filing; amendments to credit agreements, warrants, and voting agreement were entered into.
2026-01-26	Date of filing of this Amendment No. 14 to Schedule 13D.
2027-06-01	New maturity date for the Convertible Credit Agreement, July 2023 Credit Agreement, March 2024 Credit Agreement, and March 2025 Credit Agreement.
2031-01-26	New expiration date for the January 2021, March 2021, February 2022, and March 2022 Warrants, and the Second A&R Voting Agreement (unless FDA approval occurs earlier).

Recommendation

hold

This filing primarily details extensions of existing financing and governance agreements with a major shareholder, Innoviva. While these extensions provide Armata with continued financial stability and runway, they do not introduce new operational performance data or significant strategic shifts that would warrant a change in investment thesis. The high beneficial ownership and potential for future dilution remain key considerations. Therefore, a 'hold' recommendation is appropriate, advising investors to maintain their current position while monitoring future operational and financial results.

Keywords

Armata Pharmaceuticals, Innoviva, Schedule 13D, Beneficial Ownership, Credit Agreement, Warrants, Convertible Debt, Voting Agreement, Biotechnology, Pharmaceuticals, SEC Filing, Corporate Governance

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.